Phase II study of TS-1+PSK therapy as adjuvant chemotherapy during 2years against advanced gastric cancer.
- Conditions
- Advanced gastric cancer
- Registration Number
- JPRN-UMIN000004419
- Lead Sponsor
- Toho University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 300
Not provided
1.Patient with metachronous or synchronous multicancer 2.Patient who contraindicates to TS-1 3.Patient who requires continuous use of flucytosine, phenytoin or warfarin potassium 4.Patient who has experienced serious drug allergy over grade 3 in the past 5.Patient with serious complications including paralysis of intestine, ileus, interstitial pneumonitis, fibroid lung, uncontrollable diabetes mellitus, heart insufficiency, renal insufficiency or hepatic insufficiency 6.Patient with diarrhea (watery stool) 7.Patient who is pregnant or in lactation, or wish to become pregnant during this study 8.Patient who is judged to be inappropriate as subject to this study by the principal investigator or the doctors in charge
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method